Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences
May 12 2021 - 6:15PM
Business Wire
2021 RBC Capital Markets Global
Healthcare Conference on May 19, 2021 at 3:05
pm ET
Oppenheimer Rare & Orphan Disease
Summit on Friday May 21, 2021 at 4:35 pm ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
clinical-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced its participation in
a virtual fireside chat at the 2021 RBC Capital Markets Global
Healthcare Conference and a virtual presentation at the Oppenheimer
Rare & Orphan Disease Summit.
Conference Details:
Event:
2021 RBC Capital Markets Global Healthcare
Conference
Date:
Wednesday, May 19, 2021
Time:
3:05 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of Research and Development
Kamran Alam, Chief Financial Officer
Event:
Oppenheimer Rare & Orphan Disease
Summit
Date:
Friday, May 21, 2021
Time:
4:35 pm ET
Format:
Presentation
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of Research and Development
Kamran Alam, Chief Financial Officer
Webcasts for these conferences will be available in the “Events
& Media” section of the Taysha corporate website at
https://ir.tayshagtx.com/news-events/events-presentations. Archived
versions of the webcasts will be available on the website for 60
days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210512006057/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Canale Communications
carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024